Medtronic has announced the first subject enrolment in the PELE trial, aiming to assess the Onyx liquid embolic system (LES).

The US Food and Drug Administration (FDA) has granted 510(k) clearance for Tempus AI’s ECG-Low (ejection fraction) EF software.

The medical device industry faces being pulled into a broader contest over control, sovereignty and industrial self-sufficiency.